Innoviva (INVA) Stock Forecast & Price Target

Innoviva is supported by a durable royalty engine from Breo and Anoro, with an estimated ~$1.0B of royalty revenue over the next five years and little perceived Paragraph IV risk, creating a strong, high-margin cash base that should largely flow to the bottom line. Its operating businesses are also gaining traction, as 2Q26 WW product sales of $51.8M exceeded expectations and U.S. IST revenue rose 26% year over year to $36.6M, led by XacDuro and Giapreza, while the company also generated milestone and licensing revenue from Zai Lab, Dr. Reddy’s, and GARDP. Beyond these near-term catalysts, management is expanding through capital-efficient strategic assets such as Nortiva’s LYNX platform and Armata’s phage-based antibiotic program, while 1Q26 cash of $603.1M and the $191.2M fair-value gain underscore financial flexibility.

Innoviva is facing weaker fundamentals as its core royalty business fell to $59.8M, down 11% y/y, amid U.S. pricing pressure and softer inhaled respiratory demand, while FactSet consensus for 2026/2027 has declined about 6%-7%. Innoviva is also exposed to meaningful asset-value volatility, as Armata shares declined about 28% in 3Q26, implying roughly $45M in equity losses plus $17M-$20M in warrant markdowns, while Zevtera sales remain flat at about $0.4M and expectations have been cut sharply. Innoviva is further burdened by execution and capital allocation risk, since future growth depends on successful commercialization of GIAPREZA, NUZOLVENCE, and ZEVTERA, yet the company still carries $258.1M of debt against $603.1M in cash and faces possible generic erosion, partnership risk, and long-term dilution.